Abstract:Background: Primary Sjogren syndrome (pSS) is a chronic autoimmune disorder affecting 0.2–3% of the population. However, there are currently no effective systemic therapies. Anti-Ro, anti-La and rheumatoid factor(RF) as well as hyper γ-globulinaemia indicate a degree of B cell hyperactivity. In the recent ten years, iguratimod (T-614) has been used to treat RA as a novel immunomodulatory, which functions by suppressing the production of some inflammatory cytokines, as well as reducing immunoglobulin production by acting directly on human B lymphocytes without affecting B lymphocyte proliferation. Objectives: We evaluated the effectiveness and safety of iguratimod on pSS patients in this follow up study. Methods: A total of 21 pSS patients without severe systemic damage needing corticosteroid were recruited to receive iguratimod 25mg Bid for 12 weeks. Results: Among them, 1 patient and 2 patients withdrew because of kidney dysfunction and ineffectiveness. For those 18 patients who finished the follow up, 94.4% were females and average age were 46.5±13.8 year-old with median disease duration of 22.0 (9.8, 58.5) months. Compared with baseline, ESSDAI score, hyperglobulinaemia and ESR was significant decreased after iguratimod treatment (Table). Two of the 18 patients presented with decreased white blood cell count. This side effect ameliorated in one patient after tapering the dose to 25mg Qd and in another patient after 2 weeks without any intervention. Table. Effectiveness of iguratimod in pSS Baseline (B) 12w P value(vs. B) 24w P value(vs.12W) P value(vs. B) IgG 23.19±5.50 20.19±5.21 0.009 18.52±4.64 0.064 0.001 IgM 1.27±0.39 0.98±0.42 0.000 0.97±0.39 0.908 0.001 IgA 4.16±1.30 3.51±1.41 0.000 3.29±1.07 0.045 0.000 ESR 26.69±17.68 19.62±10.89 0.015 15.57±11.28 0.929 0.043 ESSDAI 4.5±2.5 3.0±2.4 0.001 2.08±1.44 0.237 0.004 Conclusion: This is the first follow study of iguratimod in pSS to show benefit with good tolerance. References [1] Saraux, A., et al. (2016). “Treatment of primary Sjogren syndrome.” Nat Rev Rheumatol 12(8): 456-471. [2] Li, J., et al. (2013). “Efficacy and safety of iguratimod for the treatment of rheumatoid arthritis.” Clin Dev Immunol 2013: 310628. [3] Ramos-Casals, M., et al. (2010). “Treatment of primary Sjogren syndrome: a systematic review.” JAMA 304(4): 452-460. Disclosure of Interests: Hui Gao Grant/research support from: This work was supported by grant from PANDA (Z-2014-06-2-1637)., Xiao-ying Zhang: None declared, Xue-wu Zhang: None declared, Zhanguo Li: None declared

The efficacy and mechanism for action of iguratimod in primary Sjögren’s syndrome patients

Total Glucosides of Peony Ameliorates Sjögren's Syndrome by Affecting Th1/Th2 Cytokine Balance.

AB0465 EFFICACY AND SAFETY OF IGURATIMOD IN PATIENTS WITH PRIMARY SJOGREN SYNDROME: A FOLLOW-UP STUDY

Clinical study of effectiveness and safety of Iguratimod in treating primary Sj(o)gren's syndrome

Follicular Helper T Cells and Follicular Regulatory T Cells in the Immunopathology of Primary Sjögren's Syndrome

Follicular helper T cells and follicular regulatory T cells in the immunopathology of primary Sjogren's syndrome

Effect of Chinese Herbal Medicines for Nourishing Yin, Supplementing Qi, and Activating Blood on Reproductive Endocrine Activity and Immune Functions in Patients with Primary Sjogren's Syndrome.

Iguratimod Suppresses Plasma Cell Differentiation and Ameliorates Experimental Sjögren’s Syndrome in Mice by Promoting TEC Kinase Degradation

Iguratimod suppresses plasma cell differentiation and ameliorates experimental Sjögren's syndrome in mice by promoting TEC kinase degradation

Efficacy and safety of iguratimod combined with methylprednisolone for primary Sjögren's syndrome: a meta-analysis and trial sequential analysis

Efficacy and safety of iguratimod in the treatment of rheumatic and autoimmune diseases: a meta-analysis and systematic review of 84 randomized controlled trials

Rituximab Therapy for Primary Sjögren’s Syndrome

Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sjögren Syndrome: A Randomized Clinical Trial

Expression of FcγRⅡb on peripheral B cells and its clinical significance in patients with primary Sj(o)gren's syndrome

High-dose Methylprednisolone Pulse Therapy Upregulated FcγRIIb Expression on B Cells in Primary Sjögren’s Syndrome Patients with Thrombocytopenia

Targeted Therapy for Primary Sjögren’s Syndrome: Where are We Now?

Efficacy and Safety of Telitacicept in Primary Sjögren’s Syndrome: a Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial

A randomized, double-blind, placebo-controlled, parallel group study on the effects of a cathepsin S inhibitor in primary Sjögren's syndrome

High-Dose Methylprednisolone Pulse Therapy Upregulated Fc Gamma Riib Expression On B Cells In Primary Sjogren'S Syndrome Patients With Thrombocytopenia

Treatment of primary Sjögren’s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity

Efficacy and safety of telitacicept in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial